monoclonal antibody therapy

Uniquity Bio seeks to investigate compounds that might otherwise sit on the shelf forever. Their lead compound appears poised to prove their model works.

Lundbeck Therapeutics is testing a monoclonal antibody that targets a novel neuropeptide in a Phase 2b clinical trial. 

Novartis’ iscalimab may improve troubling symptoms in patients with Sjögren’s disease, though there may be safety concerns to address.

Antibodies that simultaneously target two distinct antigens overcome cancer therapy resistance by addressing antigenic diversity and diminished T cell action.